Tecan Group AG · SIX:TECN

Tecan — Tecan Symposium 2010

26 slides from Tecan's conference presentation, 2010

  1. Slide 1: Applying Genomics

    Applying Genomics A Rationale For Genomic Profiling in the Clinics F d i Zenhausern, Frederic Z h PhD MBA PhD., Professor & Director, ANBM Center, University of Arizona; Assoc. Dir. MDTV Division, Translational Genomics Research Institute (TGen) Di PMRL Dir. PMRL, SScottsdale tt d l Cli Clinical i l

  2. Slide 2: Outline

    Outline Applying Genomics in Medical & Public Health Context The Th Approach A h and d Advanced Ad d Tool T l Set S t  “Omics”, Miniaturization, Next Gen Sequencing... Toward A Precise, Intelligent, Personalized Medicine Translational Development  Clinical Examples The 6th Vital Sign: Viewpoint fr

  3. Slide 3: What is the 6th Vital Sign?

    What is the 6th Vital Sign? 1. Blood pressure 2. Pulse 3. Respiration 4. Temperature 5. Pain 6. Context of Vulnerabilityy Unifying molecular diagnostics and therapeutics for a precise and personal care

  4. Slide 4: Emergency Response Medicine

    Emergency Response Medicine Who will need: •Medical M di l Triage Ti > 2 Gy? G ? • Mitigating Agent ? • Bone Marrow Transplant?

  5. Slide 5: Medical Countermeasures Against Radiation

    Medical Countermeasures Against Radiation Doctors May Risk Overuse of CT Scans November 29, 2007 U.S. not prepared for ‘dirty bomb’ attack Radiation Over‐exposure Congressional report: Nation lacks labs to test in 16 hospitals in CA for contamination after blast July, 2010 Medical scandal in France

  6. Slide 6: Logistics for Medical Countermeasures

    Logistics for Medical Countermeasures Specimen collection / identification / processing / Interpretation

  7. Slide 7: Platform Developments Diagnostics Assays

    Platform Developments Diagnostics Assays Discoveryy Test sample In Ex Ex vivo Ex vivo Control 1.5 Gy 0.5 8G y S. A. Amundson, et al. Radiat. Res. (2000)

  8. Slide 8: 74 genes separating samples by dose

    74 genes separating samples by dose Panel correctlyy predicted p p after either 6hrs or 24hrs 98% of samples Classifying of 10 samples from each dose (5 each at 6 and 24 hours after exposure) using leave one out and nearest centroid classifier Dose (G y ) Sensitivity Specificity F ive ‐dos e pre dic

  9. Slide 9: Biomarker Performances, Classifiers

    Biomarker Performances, Classifiers • Excellent E ll t – Single biomarkers ensemble classifier – Single components each competent classifiers – Clear connection with process – Simple decision by voting – Modest numbers of samples required to validate • Acceptable – Multiple biomarker aggregate class

  10. Slide 10: Outline

    Outline Applying Genomics in Medical & Public Health Context The Th Approach A h and d Advanced Ad d Tool T l Set S t  “Omics”, Miniaturization, Next Gen Sequencing Toward A Precise, Intelligent, Personalized Medicine Translational Development  Enabling Workflow Integration and Miniaturization  C

  11. Slide 11: Workflow Integration and Miniaturization

    Workflow Integration and Miniaturization 1. Sample Preparation 2. 2 DNA Quantification Q tifi ti 3. 3 DNA Amplification A lifi ti 4. 4 Detection D i 6’ 4’ 4 6’ 6 3’ 3 6’ 6 6’ 6 6’ 8’ 45’ Real‐estate for conventional Lab equipment Nanofluidics J. Gu, F. Zenhausern et al., LOC, 2007 Plastic Electronic

  12. Slide 12: Miniaturization - Deterministic Hydrodynamic Chip

    Miniaturization ‐ Deterministic Hydrodynamic Chip

  13. Slide 13: Circulating Biomarkers – Metastatic Breast Cancer

    Circulating Biomarkers – Metastatic Breast Cancer • only 27% of women diagnosed with MBC will survive to 5 years, median survival of 18 months; • Lackingg ways y to monitoringg response p to therapy py and detectingg recurrence: often relying on clinician’s experiences and bias • Current serum tumor

  14. Slide 14: Next Gen Platforms – Grand challenge

    Next Gen Platforms – Grand challenge nCP CP Fabrication F b i i off High Hi h Density D i DNA Nanoarray N for f Sequencing S i byb Hybridization H b idi i A C A C G T Stamp-2 Inking: Round 1 Gphosphoramidite Stamp-2 Printing Stamp-1 T OH T OHT Stamp-2 A C G T A C G T A C G T C G T Inking: Tphosphora

  15. Slide 15: Printed high density nanoarrays (10 billion/cm2)

    Printed high density nanoarrays (10 billion/cm2) nCP Stamp Cold welded Au array Sub‐100 nm Alignment Streptavidin protein array 100 nm size/250 nm period 5 µm

  16. Slide 16: Multilayer Printing of Nucleoside Phosphoramidite on Nanoarray

    Multilayer Printing of Nucleoside Phosphoramidite on Nanoarray

  17. Slide 17: Personal Genomics on the Next Gen Platform

    Personal Genomics on the Next Gen Platform: Genomic Data Generation/Capture SOLiD Sequencing and Genome Interrogation John Carpten Whole Genome Sequencing @ 30X Coverage; Tumor and Matched Normal DNA • Point Mutations • Indels • Translocations and Breakpoints • Copy Number • SNP Data from Drug Metab

  18. Slide 18: Genome Sequencing Data Analysis

    Genome Sequencing Data Analysis Computing time (wall‐time) per sample David Craig Whole Genome Alignment (based on corona_lite software) 400 Million 35 mer run takes 3 days 1200M reads will take ~ 9 days @ 35 mer 50 mers, ~ 15 days (20x) Ed Suh Annotation and Conversion to standard format  2‐days

  19. Slide 19: Outline

    Outline Applying Genomics in Medical & Public Health Context The Th Approach A h and d Advanced Ad d Tool T l Set S t  “Omics”, Miniaturization, Next Gen Sequencing Toward A Precise, Intelligent, Personalized Medicine Translational Development  Clinical Examples The 6th Vital Sign: Viewpoint from

  20. Slide 20: A Lot of People Talk About Personalized Medicine

    A Lot of People Talk About Personalized Medicine 1. But who is really doing it? 2 All physicians 2. h i i try t tot practice ti personalized li d medicine • Take good care of a person 3 Let’s 3. L t’ consider id another th term t • “Precision Medicine” (because nurses and doctors already practice pe

  21. Slide 21: Clinical Studies To Test Personalized Genomics

    Clinical Studies To Test Personalized Genomics 11,935 participants i i in i 460 phase h I (first (fi in i patients) i ) trials i l new anticancer agents led to a response rate (shrink by ≥ 30%) = 4.4% Validate hypothesis that we can help patients with Refractory Advanced Cancer by profiling individu

  22. Slide 22: Target Now (pilot trial)

    Target Now (pilot trial) 1. 1 112 patients referred for phase I studies (had exhausted conventional chemotherapy options, undergoing procedures for a cancer‐related matter – e.g. obstruction) 2. Patients tissues submitted for molecular profiling in 2 formats: (i) Paraffin embedded tumor samples subm

  23. Slide 23: Methods– Overview Mechanics

    Methods– Overview Mechanics 9 national sites Selection of treatment for the patient based on MP results – via i the h following f ll i algorithm l ih • IHC/FISH and microarray indicates same target • IHC positive result alone • Microarray positive result alone

  24. Slide 24: Results: Primary Endpoint: PFS Ratio ≥ 1.3 By Tumor Type

    Results: Primary Endpoint: PFS Ratio ≥ 1.3 By Tumor Type Tumor type Total treated Number with PFS ratio≥ 1.3 (%) Breast 18 8 44 Colorectal 11 4 36 Ovarian 5 1 20 Miscellaneous* 32 5 16 66 18 27 Miscellaneous tumor types with PFS ratio ≥ 1.3 included: lung 1/3, Cholangiocarcinoma 1/2, Mesothelioma 1/

  25. Slide 25: Conclusion

    Conclusion • “Applied” Genomics is translating in clinical settings for personal care, as well as in emergency response • Multidimensional information requires combining a multitude of advanced molecular tools and sophisticated algorithms g and databases to recover intelligent g knowledge • New clin

  26. Slide 26: Acknowledgments

    Acknowledgments SCRI / Tgen Clinical Services UofA/TGen • D. von Hoff • M. Brengues M • R. Ramanathan • J. Gu • M. Bittner • J. Yangg • J. Trent • S. Rogers • R. Korn • H. Cuntliffe • M. Slater • J. Carpenten • S. Amundson (CU) We are grateful to all our sponsors, co‐workers and all the patients and

Tecan Group — Tecan Symposium 2010 on 6ix